Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.

Trial Details

NCT ID
NCT05751798
Phase
PHASE1 / PHASE2
Sponsor
OSE Immunotherapeutics
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Part A: OSE-279 100mg
  • Part A: OSE-279 300mg
  • Part A: OSE-279 600mg
  • Part B: OSE-279 600 mg and OSE2101
  • Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive
  • Part C: OSE-279 600 mg - HLA-A2 positif
Locations (sample)
  • Anderlecht, Belgium|50.83619,4.31454
  • Edegem, Belgium|51.15662,4.44504
  • Lyon, France|45.74906,4.84789
  • Paris, France|48.85341,2.3488
  • Rennes, France|48.11109,-1.67431

Key Eligibility Criteria

  • Male or female, aged ≥ 18 years
  • Signed and dated informed consent form (ICF) prior to any trialspecific procedures.
  • ECOG performance status 0-1
  • Patients must be affiliated to a social security system or an equivalent system, if applicable as per local regulations.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →